Clinical Study
A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy
Table 1
Baseline characteristics of participants with or without conbercept pretreatment.
| | Preoperative intravitreal conbercept | Control | value |
| Number of eyes | 54 | 53 | | Sex (male) | 27 (62.79%) | 24 (53.33%) | 0.396 | Age (y) | 48.63 ± 8.24 | 49.64 ± 8.71 | 0.576 | Systemic profile | | | | Type of diabetes | | | 0.517 | 1 | 6 (13.95%) | 4 (8.89%) | | 2 | 37 (86.05%) | 41 (91.11%) | | HbA1c at time of surgery | 7.90 ± 1.14 | 7.63 ± 1.24 | 0.305 | Duration of diabetes (y) | 16.67 ± 4.53 | 15.87 ± 4.77 | 0.418 | Systemic hypertension | 11 (25.58%) | 11 (24.44%) | 1.000 | Ocular profile | | | | Study eye (left/right) | 19/35 (35.19%/64.81%) | 21/32 (39.62%/60.38%) | 0.692 | Previous history of laser | 11 (20.37%) | 16 (30.19%) | 0.272 | Lens status (pseudophakic/phakic) | 11/43 (20.37%/79.63%) | 8/45 (15.09%/84.91%) | 0.614 | Pathogeny | | | 0.869 | Nonclearing vitreous hemorrhage | 22 (40.74%) | 23 (43.40%) | | Diffuse fibrovascular proliferation | 27 (50.00%) | 24 (45.28%) | | Traction retinal detachment | 5 (9.26%) | 6 (11.32%) | | Extent of vitreoretinal adhesion grade | | | 0.604 | 3 | 17 (31.48%) | 19 (35.85%) | | 2 | 19 (35.19%) | 21 (39.62%) | | 1 | 18 (33.33%) | 13 (24.53%) | | 0 | 0 (0%) | 0 (0%) | |
|
|
HbA1c: glycosylated hemoglobin A1c.
|